Is Astrazeneca Pharma India Ltd debt-free?

Yes, Astrazeneca Pharma India Ltd is debt-free with a debt-to-equity ratio of 0.05.

Home

Astrazeneca Pharma India Ltd

Astrazeneca Pharma India Ltd Financials

Astrazeneca Pharma India Ltd Financial Statement

Astrazeneca Pharma India Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Mar 2025	Dec 2024	Sep 2024
Revenue	496.63	448.27	416.15
Operating Expense	399.79	396.85	355.46
Net Profit	58.25	30.85	38.43
Net Profit Margin	11.73	6.88	9.23
Earning Per Share	23.30	12.34	16.37
EBIDTA	99.54	52.42	62.79
Effective Tax Rate	23.67	23.67	24.22

Particulars	Mar 2025
Revenue	496.63
Operating Expense	399.79
Net Profit	58.25
Net Profit Margin	11.73
Earning Per Share	23.30
EBIDTA	99.54
Effective Tax Rate	23.67

Astrazeneca Pharma India Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Total Revenue Annual	1,716.29	1,295.53	1,002.97
Operating Expenses Annual	1,462.32	1,111.08	837.85
Operating Profit Annual	197.81	235.68	150.99
Interest Annual	1.46	1.20	0.63
Depreciation	38.54	14.81	16.26
Net Profit Annual	115.74	161.51	99.29
Tax Annual	40.62	58.03	34.81

Particulars	Mar 2025
Total Revenue Annual	1,716.29
Operating Expenses Annual	1,462.32
Operating Profit Annual	197.81
Interest Annual	1.46
Depreciation	38.54
Net Profit Annual	115.74
Tax Annual	40.62

Astrazeneca Pharma India Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Cash Flow at the Beginning	505.57	500.34	448.42
Cash Flow from Operations	65.36	27.87	58.29
Cash Flow from Investing	30.80	21.74	18.11
Cash Flow from Financing	-65.59	-44.38	-24.48
Cash Flow at the End	536.14	505.57	500.34

Particulars	Mar 2025
Cash Flow at the Beginning	505.57
Cash Flow from Operations	65.36
Cash Flow from Investing	30.80
Cash Flow from Financing	-65.59
Cash Flow at the End	536.14

Astrazeneca Pharma India Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
PBDIT Margin (%)	17.15	18.19	18.82
PBIT Margin (%)	14.82	17.04	17.20
PBT Margin (%)	4.67	2.84	-10.09
Net PROFIT Margin (%)	6.74	12.47	9.90
Return On Networth / Equity (%)	23.63	24.84	22.95
Return On Networth /Employed (%)	32.94	33.26	30.47
Return On Assets (%)	14.97	24.31	17.52
Total Debt / Equity (X)	0.03	0.01	0.01
Asset Turnover Ratio (%)	2.22	1.95	1.77

Particulars	Mar 2025
PBDIT Margin (%)	17.15
PBIT Margin (%)	14.82
PBT Margin (%)	4.67
Net PROFIT Margin (%)	6.74
Return On Networth / Equity (%)	23.63
Return On Networth /Employed (%)	32.94
Return On Assets (%)	14.97
Total Debt / Equity (X)	0.03
Asset Turnover Ratio (%)	2.22

Astrazeneca Pharma India Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Fixed Assets Annual	64.24	66.68	68.86
Total Current Assets Annual	1,342.35	932.71	835.47
Non Current Assets Annual	175.77	145.32	149.40
Total Shareholders Funds Annual	770.35	711.92	588.69
Total Assets Annual	1,518.12	1,078.03	984.87

Particulars	Mar 2025
Fixed Assets Annual	64.24
Total Current Assets Annual	1,342.35
Non Current Assets Annual	175.77
Total Shareholders Funds Annual	770.35
Total Assets Annual	1,518.12

Astrazeneca Pharma India Ltd Earning Calls

No Data Availabe

Dividend Pages

PE Ratio

FAQS on Astrazeneca Pharma India Ltd Financials

As of Aug 10, 2025, Astrazeneca Pharma India Ltd has a market capitalization of 21,515.88 Cr. Value Research classifies it as a Large-Cap company.

Yes, Astrazeneca Pharma India Ltd is with a debt-to-equity ratio of 0.05.

In FY 2024 , Astrazeneca Pharma India Ltd recorded a total revenue of approximately 1,716.29 Cr marking a significant milestone in the company's financial performance.

Astrazeneca Pharma India Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.5% and 0.3% annually, respectively..

Astrazeneca Pharma India Ltd's current PE ratio is 185.90.

Astrazeneca Pharma India Ltd's ROCE averaged 30.5% from the FY ending March 2023 to 2025, with a median of 30.8%. It peaked at 31.2% in March 2025, reflecting strong capital efficiency over the period..

Astrazeneca Pharma India Ltd's latest EBIT is Rs. 157.82 Cr, surpassing the average EBIT of Rs. 171.10 Cr over the 5 years..